Mackenzie Financial Corp Purchases 4,260 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Mackenzie Financial Corp increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 17.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,057 shares of the biopharmaceutical company’s stock after buying an additional 4,260 shares during the period. Mackenzie Financial Corp’s holdings in Amicus Therapeutics were worth $412,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vontobel Holding Ltd. bought a new stake in Amicus Therapeutics in the fourth quarter valued at $1,173,000. Mutual of America Capital Management LLC increased its stake in Amicus Therapeutics by 27.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 217,859 shares of the biopharmaceutical company’s stock valued at $3,091,000 after purchasing an additional 46,762 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Amicus Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 229,604 shares of the biopharmaceutical company’s stock valued at $3,258,000 after purchasing an additional 19,204 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Amicus Therapeutics by 360.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,920 shares of the biopharmaceutical company’s stock valued at $481,000 after purchasing an additional 26,552 shares in the last quarter. Finally, Diversified Trust Co increased its stake in Amicus Therapeutics by 8.0% in the fourth quarter. Diversified Trust Co now owns 62,695 shares of the biopharmaceutical company’s stock valued at $890,000 after purchasing an additional 4,633 shares in the last quarter.

Amicus Therapeutics Stock Up 1.1 %

Shares of NASDAQ FOLD opened at $10.28 on Friday. The stock has a market capitalization of $3.04 billion, a P/E ratio of -20.16 and a beta of 0.75. The company has a 50-day moving average price of $11.88 and a 200-day moving average price of $11.99. Amicus Therapeutics, Inc. has a 1 year low of $9.70 and a 1 year high of $14.57. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.88 and a quick ratio of 2.52.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The firm had revenue of $115.08 million for the quarter, compared to analysts’ expectations of $115.11 million. On average, equities research analysts forecast that Amicus Therapeutics, Inc. will post 0.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on FOLD. JPMorgan Chase & Co. reduced their price objective on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, March 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a report on Thursday, February 29th.

Insider Buying and Selling

In related news, Director Margaret G. Mcglynn sold 7,500 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.40, for a total transaction of $100,500.00. Following the transaction, the director now directly owns 59,289 shares in the company, valued at $794,472.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Margaret G. Mcglynn sold 7,500 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.40, for a total transaction of $100,500.00. Following the transaction, the director now directly owns 59,289 shares in the company, valued at $794,472.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 4,167 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $58,338.00. Following the transaction, the chief executive officer now owns 871,219 shares in the company, valued at $12,197,066. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 48,108 shares of company stock worth $662,605. 2.10% of the stock is owned by insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.